ONCOSIL MEDICAL LTD (ASX:OSL) Announces Security Consolidation
ONCOSIL MEDICAL LTD (ASX:OSL) announces a 400-to-1 security consolidation, outlining the consolidation ratio, timetable, and impact on securities.
Category: Healthcare
Imricor Medical Systems (ASX:IMR) Announces First Real-time MRI-guided Ablations at Semmelweis University
Imricor Medical Systems (ASX:IMR) initiates real-time MRI-guided ablation procedures at Hungary’s Semmelweis University, marking key European expansion.
AdAlta Limited (ASX:1AD) Reports Q3 FY25 Progress on Immunotherapy Strategy
AdAlta Limited (ASX:1AD) reports significant advancements in its cellular immunotherapy strategy and outlines financial updates for Q3 FY25.
Race Oncology (ASX:RAC) Announces Safe Dosing of First Patient in Phase 1 RC220 Trial
Race Oncology (ASX:RAC) successfully dosed the first patient in the Phase 1 RC220 trial for advanced solid tumours, marking a key milestone.
Dimerix Limited (ASX:DXB) Secures Major Licensing Deal in Japan and FDA Endorsement for DMX-200
Dimerix Limited (ASX:DXB) secures a ¥10.5 billion licensing deal in Japan and receives FDA endorsement for its DMX-200 therapy.
BPH Global Limited (ASX:BP8) Releases Quarterly Activities Report and Secures Funding
BPH Global Limited (ASX:BP8) releases Q1 2025 report, secures $609K funding, and advances Indonesian seaweed projects.
ImpediMed Limited (ASX:IPD) Announces Q3 Revenue and ARR Growth
ImpediMed Limited (ASX:IPD) reports record Q3 revenue and ARR growth, along with key operational and management developments.
Mesoblast Limited (ASX:MSB) Announces Q3 2025 Highlights
Mesoblast Limited (ASX:MSB) reports Q1 2025 milestones, including the US launch of Ryoncil® and strong financial performance.
EMVision Medical Devices Limited (ASX:EMV) Launches Clinical Trial for emu™ Device
EMVision Medical Devices Limited (ASX:EMV) has commenced pivotal clinical trials for its emu™ brain scanner and announced successful device testing and robust cash reserves.
Starpharma (ASX:SPL) Announces Q3 FY25 Activities Report
Starpharma (ASX:SPL) announces Q3 FY25 report with advancements in partnerships, product launches, and financial performance.